CYGNOS BioTech, LLC Selected for U.S. Department of Defense SBIR Phase II Negotiation to Advance Broad-Spectrum Antiviral Platform
Miami, FL – January 5, 2026
CYGNOS BioTech, LLC is pleased to announce that its Small Business Innovation Research (SBIR) Phase II proposal has been selected by the U.S. Department of Defense for contract negotiation, marking a significant milestone in the continued development of its PVX antiviral biologic platform.
Following the successful completion of SBIR Phase I, the Phase II program is designed to advance PVX toward prototype-level maturity through expanded manufacturing scale-up, analytical characterization, and functional antiviral validation. PVX is a host-directed, virus-agnostic antiviral biologic being developed to address current and emerging viral threats of relevance to both military and civilian populations.
CYGNOS BioTech is a Florida-based biotechnology company focused on the development of antiviral and anticancer biologics, with established experience in veterinary drug development. The proposed Phase II effort is supported through the Department of Defense SBIR program administered by the Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) and is aligned with DoD priorities in force health protection, biodefense preparedness, and rapid response to emerging biological threats.
The program represents a critical component of CYGNOS’ One Health strategy, leveraging prior veterinary development to accelerate translation toward human use. CYGNOS currently holds multiple Investigational New Animal Drug (INAD) authorizations through the FDA’s Center for Veterinary Medicine (CVM), which provide a foundation for advancing PVX along a staged regulatory pathway bridging veterinary and future human IND development.
Phase II activities are intended to further integrate manufacturing, functional, and regulatory-enabling data packages, positioning PVX as a scalable antiviral countermeasure capable of supporting both military readiness and broader public-health preparedness.
Dr. Jay E. Yourist, Founder and President of CYGNOS BioTech, LLC, stated:
“Selection for SBIR Phase II negotiation reflects the strength of our underlying science and the relevance of PVX to Department of Defense mission needs. This next phase enables us to advance PVX toward integrated readiness while maintaining a clear One Health pathway bridging veterinary and human antiviral applications.”
CYGNOS continues to collaborate with government agencies, industry partners, academic institutions, and non-profit organizations to ensure development efforts remain aligned with operational, regulatory, and transition requirements.
For additional information about CYGNOS BioTech and its antiviral development programs, please contact info@cygnosbiotech.com or visit www.cygnosbiotech.com.
Reference to the Department of Defense, the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense, or any other agency of the United States Government does not constitute or imply endorsement or recommendation by the United States Government or any agency thereof.